Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: An idea whose time for testing is coming, part I

Circulation

Volumn 104, Issue 19, 2001, Pages 2376-2383

  Shah, Prediman K ^a,c,d,e   Kaul, Sanjay ^a   Nilsson, Jan ^b   Cercek, Bojan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MALMÖ UNIVERSITY   (Sweden)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d TMJ Association   (United States)

^e Esperion Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN;

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HEART PROTECTION; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THROMBOSIS;

EID: 0035818556     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/hc4401.098467     Document Type: Review

References (156)

1. Atherosclerosis is an inflammatory disease
2. Plaque disruption and thrombosis: Potential role of inflammation and infection
3. Present concepts of coronary atherosclerosis-thrombosis, therapeutic implications, and perspectives
4. Involvement of the immune system in human atherogenesis: Current knowledge and unanswered questions
5. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT (Multiple Risk Factor Intervention Trial)
6. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
7. Lipoprotein(a) concentrations as risk indicators for atherosclerosis
8. Associations of lipoprotein cholesterols, apolipoproteins A-I and B. and triglycerides with carotid atherosclerosis and coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
9. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease
10. The Tromso heart-study: Highdensity lipoprotein and coronary heart disease: A prospective casecontrol study
11. High density lipoproteins and atherosclerosis
12. Associations of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis
13. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: The Framingham Study
14. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study
15. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study
16. Lipoproteins, cardiovascular disease, and death: The Framingham study
17. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
18. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)
19. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
20. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial investigators
21. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group
22. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
23. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS (Air Force/Texas Coronary Atherosclerosis Prevention Study)
24. Heart attacks: Gone with the century?
25. High density lipoproteins in health and in disease
26. Serum apolipoprotein levels in relation to acute myocardial infarction and its risk factors: Apolipoprotein A-I levels in male survivors of myocardial infarction
27. Apolipoprotein A-I containing lipoproteins in coronary artery disease
28. HDL-cholesterol or apolipoprotein Al: Which parameter to choose?
29. The role of apolipoprotein A-I-containing lipoproteins in atherosclerosis
30. Apolipoprotein- A-I-containing particles and atherosclerosis
31. Low high density lipoprotein level is associated with increased restenosis rate after coronary angioplasty
32. Effects of serum lipid levels on restenosis after coronary angioplasty
33. Relation of plasma lipid and apoprotein levels to progressive intimal hyperplasia after arterial endarterectomy
34. Serum lipids and lipoproteins in relation to restenosis after coronary angioplasty
35. Milano apoprotein: Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family
36. Very low high-density lipoproteins without coronary atherosclerosis
37. CETP deficiency
38. Molecular genetics of cholesterol transport and cholesterol reverse transport disorders (familial hypercholesterolemia and CETP deficiency) and coronary heart disease
39. Cholesteryl ester transfer protein activity enhances plasma cholesteryl ester formation: Studies in CETP transgenic mice and human genetic CETP deficiency
40. Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan: Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity
41. Is cholesteryl ester transfer protein (CETP) deficiency atherogenic in familial hypercholesterolemia
42. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation
43. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels
44. Cholesteryl ester transfer protein and atherogenesis
45. George Lyman Duff memorial lecture: Lipid transfer proteins, HDL metabolism, and atherogenesis
46. Cholesteryl ester transfer protein gene polymorphisms are associated with carotid atherosclerosis in men
47. High plasma HDL concentration associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin: Cholesterol acyl transferase
48. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces Atherosclerosis in cholesterol-fed LDL-receptor deficient mice
49. HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis
50. Apo A-I deficiency causes both hypertriglyceridemia and increased atherosclerosis in human apo B transgenic mice
51. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits
52. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit
53. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits
54. Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice
55. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E- deficient mouse
56. Apolipoprotein AI transgene corrects apolipoprotein E deficiency- induced atherosclerosis in mice
57. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein[a] in transgenic mice
58. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I-transgenic rabbits
59. Somatic gene transfer of human apoA-I inhibits atherosclerosis progression in mouse models
60. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice
61. Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits
62. Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits
63. Reconstituted HDL containing human apolipoprotein A-I reduces VCAM-l expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice
64. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formation after endothelial denudation in apo E-deficient mice
65. The Helsinki Heart Study: Central findings and clinical implications
66. Report on the Lipid Research Clinic trials
67. Effect of benzafibrate treatment over 5 years on coronary plaques causing 20% to 50% diameter narrowing: The Benzafibrate Coronary Atherosclerosis Intervention Trial (BECAIT)
68. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol: Lopid Coronary Angiography Trial (LOCAT) Study Group
69. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The bezafibrate infarction prevention (BIP) study
70. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group
71. High-density lipoproteins, reverse cholesterol transport and atherosclerosis: Recent developments
72. Atherosclerosis and lipoprotein metabolism: Role of reverse cholesterol transport
73. High-density lipoprotein cholesterol levels as a marker of reverse cholesterol transport
74. Basic considerations in the reversal of atherosclerosis: Significance of high-density lipoprotein in stimulating reverse cholesterol transport
75. Atheroprotective mechanisms of HDL
76. Reverse cholesterol transport and atherosclerosis regression
77. Mechanistic studies of high-density lipoproteins
78. Reverse cholesterol transport and use of transgenic mice and rabbits to reveal candidate genes for protection against atherosclerosis
79. Reverse cholesterol transport: A review of the process and its clinical implications
80. HDL receptors and cholesterol efflux from parenchymal cells
81. Reverse cholesterol transport: Physiology and pharmacology
82. Role of high density lipoproteins in the regression of atherosclerosis
83. Physiologic role and clinical significance of reverse cholesterol transport
84. Remodeling and shuttling: Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol
85. Cell cholesterol efflux: Integration of old and new observations provides new insights
86. Molecular cloning of the human ATP-binding cassette transporter l (hABCI): Evidence for steroldependent regulation in macrophages
87. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux
88. Role of ABC1 gene in cholesterol efflux and atheroprotection
89. ABCAl-mediated transport of cellular cholesterol and phospholipids to HDL apolipoproteins
90. The gene encoding ATP-binding cassette transporter I is mutated in Tangier disease
91. The Tangier disease gene product ABCI controls the cellular apolipoprotein-mediated lipid removal pathway
92. Human ATP-binding cassette transporter 1 (ABC1): Genomic organization and identification of the genetic defect in the original Tangier disease kindred
93. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
94. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor
95. Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface
96. Comparison of class B scavenger receptors, CD36 and scavenger receptor BI (SR-BI), shows that both receptors mediate high density lipoprotein-cholesteryl ester selective uptake but SR-BI exhibits a unique enhancement of cholesteryl ester uptake
97. Of plaques and stones: The SR-BI (scavenger receptor class B, type 1)
98. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein
99. Milano carriers and transgenic mice
100. Milano has reduced capacity, compared with wild-type apolipoprotein A-I, to recruit membrane cholesterol
101. The yin and yang of oxidation in the development of the fatty streak: A review based on the 1994 George Lyman Duff Memorial Lecture
102. Monocyte adhesion and transmigration in atherosclerosis
103. Pathogenesis of atherosclerosis
104. Atherosclerosis: Basic mechanisms: Oxidation, inflammation, and genetics
105. Lipoprotein oxidation and gene expression in the artery wall: New opportunities for pharmacologic intervention in atherosclerosis
106. HDL apolipoprotein A-I attenuates oxidative modification of low density lipoprotein: Studies in transgenic mice
107. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men
108. High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis
109. Is paraoxonase related to atherosclerosis?
110. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
111. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins
112. The genetic mapping and gene structure of mouse paraoxonase/arylesterase
113. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins
114. Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model
115. Increased immunolocalization of paraoxonase, clusterin, and apoliprotein A-I in the human artery wall with the progression of atherosclerosis
116. Evidence for a paraoxonaseindependent inhibition of low-density lipoprotein oxidation by highdensity lipoprotein
117. Gene activation, apolipoprotein A-I/high density lipoprotein, atherosclerosis prevention and longevity
118. Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles
119. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification
120. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: Role of prooxidants vs. antioxidants
121. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states
122. Paraoxonase-gene polymorphisms associated with coronary heart disease: Support for the oxidative damage hypothesis?
123. Human serum paraoxonase
124. Paraoxonase and coronary heart disease
125. Paraoxonase inhibits highdensity lipoprotein oxidation and preserves its functions: A possible peroxidative role for paraoxonase
126. The antiatherogenic role of high-density lipoprotein cholesterol
127. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
128. Does paraoxonase play a role in susceptibility to cardiovascular disease?
129. Low serum paraoxonase: A risk factor for atherosclerotic disease?
130. Paraoxonase genes and disease
131. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation
132. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→ R genetic polymorphism
133. Role of group II secretory phospholipase A2 in atherosclerosis, 2: Potential involvement of biologically active oxidized phospholipids
134. The role of oxidized lipoproteins in atherogenesis
135. Monocyte binding to endothelial cells induced by oxidized phospholipids present in minimally oxidized low density lipoprotein is inhibited by a platelet activating factor receptor antagonist
136. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: In vitro and in vivo inhibition by WEB 2086
137. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein
138. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Steps 2 and 3
139. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein, step 1
140. Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement: Affinity of the apoproteins for polymeric C9
141. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules
142. Inhibition of endothelial cell adhesion molecule expression by high density lipoproteins
143. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway: A possible mechanism for protection against atherosclerosis by HDL
144. High density lipoprotein reverses inhibitory effect of oxidized low density lipoprotein on endotheliumdependent arterial relaxation
145. Lipoprotein-like phospholipid particles inhibit the smooth muscle cell cytotoxicity of lysophosphatidylcholine and platelet-activating factor
146. Coronary risk factors, endothelial function, and atherosclerosis: A review
147. Cholesterol, cholesterol lowering, and endothelial function
148. Coronary atherosclerotic wall thickening and vascular reactivity in humans: Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis
149. Endothelial modulation of coronary vasomotor tone in humans. Effects of atherosclerosis and risk factors for coronary artery disease
150. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute plateletdependent thrombus formation
151. Milano
152. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C
153. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man
154. Apolipoprotein E modulates low density lipoprotein retention by lipoprotein lipase anchored to the subendothelial matrix
155. The response-to-retention hypothesis of atherogenesis reinforced
156. Exploiting the vascular effects of high-density lipoprotein and its apolipoproteins: An idea whose time for testing is coming, part II